New Drug Could Transform Derma Sciences, CEO Says

One of the reasons people invest in small-cap health-care companies is the potential that a small name can hit a home run. Often, they strike out. But Derma Sciences (DSCI) could dramatically change its fortunes. With revenue of roughly $80 million this year, the medical technology company specializes in wound-care management, making goods that range [...]